Mogrol attenuates lipopolysaccharide (LPS)-induced memory impairment and neuroinflammatory responses in mice

Abstract

This study aimed to evaluate whether mogrol, a main bioactive ingredient of Siraitia grosvenorii, could attenuate LPS-induced memory impairment in mice. The behavioral tests and immunohistochemical analysis and Western blot were performed. The present results showed that oral administration of mogrol (20, 40, 80 mg/kg) significantly improved LPS-induced memory impairment in mice. The results also indicated that mogrol treatment significantly reduced the number of Iba1-positive cells, the nuclear NF-κB p65 and levels of TNF-α, IL-1β and IL-6 both in the hippocampus and frontal cortex of LPS-challenged mice.

Keywords:

• Memory impairment
• mogrol
• LPS
• inflammation
• NF-κB

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This project was supported by the Natural Science Foundation of China (81773714, 81573413 to Hao Hong and 81603113 to Su Su Tang) and the Fundamental Research Funds for the Central Universities (2632017PT01).